About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Active Not RecruitingNCT06855394

Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events

Several studies have shown that the efficacy of clopidogrel for secondary prevention of major adverse cardiovascular events (MACE), including acute coronary syndrome, depends on the polymorphism of th...

Lead sponsor: University of Florida•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Florida

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•All patients aged ≥18 years with available CYP2C19 genotyping results obtained within the predefined period.

Exclusion Criteria

•Absence of CYP2C19 genotyping results obtained within the predefined period.

Related studies

RECRUITINGPhase 4

Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)

NCT06916520 · Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)

Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease

NCT07444957 · Coronary Arterial Disease (CAD), NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI), and more

Validation of Sudden Cardiac Arrest Risk Factors in Patients With CAD

NCT07444931 · Coronary Arterial Disease (CAD), Sudden Cardiac Arrest, and more

Drug-Eluting Balloon Treatment vs. Guideline-Directed Medical Therapy for the Treatment of Lipid-Rich Plaques

NCT07107971 · Coronary Artery Disease, Atheroscleroses, and more

RECRUITINGPhase 4

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

NCT07025148 · Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 31, 2026Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

Phase—

Enrollment13,000

Start dateJan 2011

Last updatedMar 31, 2026

Condition

Atherosclerotic Vascular Disease Coronary Arterial Disease (CAD)Atherosclerosis of Coronary Artery Atherosclerosis of Arteries of the Extremities, Unspecified Heart Diseases+2 more

Locations shown

UF Health

Gainesville, Florida

UF Health

Jacksonville, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 31, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions